BioXcel Therapeutics has announced a strategic plan to investigate the development of using wearable digital device technology, such as the Apple Watch, with the goal of enhancing the prevention and treatment of agitation including, if approved, the administration of BXCL501 prior to the onset of agitation.
BioXcel plans to conduct a feasibility study with potential applications for uses in commercially available wearable digital devices to measure nervous and motor system activity relevant to both agitation and the mechanism of action of the Company’s drug candidate, BXCL501. more